Drug eluting balloons are angioplasty balloons that are coated with an anti-proliferative drug, which is eluted in vessel walls during the inflation of balloon, usually at nominal pressure with a specific minimal inflation time. The active substance coated on the drug eluting balloon should be lipophilic in nature to have a high absorption rate through the vessel wall. Mostly paclitaxel is used as active ingredient due to its high pharmacokinetic transfer rate into the vessel wall and it is actively used in drug eluting balloons in the U.S. market and has been already approved for use in Europe.

Get FREE In-Depth Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/2459

Market Dynamics

Increasing prevalence of coronary artery diseases is a major factor driving drug eluting balloon market growth. According to American College of Cardiology, June 2017, around 17.92 million cardiovascular deaths were registered in 2015 worldwide. Moreover, key players in the market are focused on adopting acquisition strategies in order to gain access to innovative products and expand their product offerings in the potential markets. For instance, in April 2010, Medtronic acquired Invatec and affiliated companies. Invatec launched 4 new drug eluting balloons in Europe in 2009 including In.Pact Amphirion, In.Pact Admiral, In.Pact Pacific, and In.Pact Falcon. Medtronic is focused on enhancing its international presence by expanding treatment option for patients with cardiovascular disease.

Increasing prevalence of coronary artery disease and diabetes is expected to propel growth of the drug eluting balloon market

Drug eluting balloon is an angioplasty balloon, which plays a vital role in treatment of coronary artery disease. High prevalence of coronary artery disease is expected to propel demand for angioplasty and other treatments, which in turn is expected to drive the market growth. According to the World Health Organization (WHO), around 3.8 million men and 4.4 million women die, annually from coronary heart disease worldwide. Moreover, the number of deaths from age 15 to 59 is around 1332 thousands and for above 60 years of age is around 5825 thousands.

Increasing adoption of drug eluting balloon in North America is expected to bolster the market growth

North America holds dominant position in the global drug eluting balloon market, owing to high prevalence of obesity, which further develops cardiovascular and coronary artery diseases. In October 2017, according to the National Center for Health Statistics (NCHS), estimated the prevalence of obesity in adults was around 39.8% and in youth 18.5% in the year 2015 -16 in the U.S. Increasing prevalence of cardiovascular diseases developed from tobacco and smoking in the region is also expected to boost the market growth.

Key Players

Major players operating in the global drug eluting balloon market include, Medtronic, Becton, Dickinson and Company (BD), Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Terumo Corporation, Surmodics, Inc., and Biotronik.

Detailed Segmentation:

Global Drug Eluting Balloon Market, By Product Type:
Coronary Drug Eluting Balloon
Peripheral Drug Eluting Balloon
Others

Global Drug Eluting Balloon Market, By End User:
Hospitals
CATH Laboratories
Ambulatory Surgical Centers
Others

Global Drug Eluting Balloon Market, By Geography:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Request For Customization of This Exclusive Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2459

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]